Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
Terminated
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +318 locations
Conditions: Malignant Neoplasm
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Completed
This randomized phase III trial studies antiemetic therapy with olanzapine to see how well they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy. Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. Olanzapine may help prevent chemotherap... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +176 locations
Conditions: Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Post-Operative Dosing of Dexamethasone in Patients with Brain Tumors After a Craniotomy, PODS Trial
Recruiting
This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, Meningioma
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
Terminated
This prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on ameliorating the signs and symptoms of dry eye disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Dry Eye
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Active Not Recruiting
The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the number of leukemia cells, but it could also cause additional side effects. Bortezomib and vorinostat have been approved by the US Food and Drug Administration (FDA) to treat other cancers in adults, but they have not be... Read More
Gender:
ALL
Ages:
365 days and below
Trial Updated:
01/10/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +16 locations
Conditions: Acute Lymphoblastic Leukemia
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
Completed
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: UCSF MS Center Site Number : 8400002, San Francisco, California +69 locations
Conditions: Plasma Cell Myeloma
Steroids in Occipital Nerve Block for Treatment of Headache
Recruiting
Currently there is limited evidence of benefit for the addition of steroids to occipital nerve blocks for treatment of headache, and not all steroids have been explored. The purpose of this research is to learn more about whether the addition of a specific kind of steroid (dexamethasone) provides any additional benefit to nerve blocks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Headache, Occipital Nerve Block
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Completed
The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/09/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Multiple Myeloma
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
Recruiting
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
RCT Comparing ESPB Solutions in Breast Surgery
Completed
The object of our research is to investigate the relative efficacy of liposomal bupivacaine administered via an Erector Spinae Plane (ESP) block as compared to our standard of care medication solution of (bupivacaine mixed with epinephrine, dexamethasone, and clonidine) for pain management in subjects undergoing bilateral surgical intervention for breast cancer. This will be an investigator-initiated, double-blind, patient-controlled, randomized control trial comparing pain scores at 48 hours af... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Dexamethasone for Post Traumatic Headache
Completed
This is a randomized study of intravenous metoclopramide + intravenous dexamethasone versus intravenous metoclopramide for patients with acute post-traumatic headache.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/08/2025
Locations: Montefiore, Bronx, New York
Conditions: Post-Traumatic Headache
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Active Not Recruiting
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving low doses of cyclophosphamide daily may reduce side effects. Dex... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8